Drug induced aseptic meningitis - Revision history

Adriack at 16:21, 12 September 2017

2017-09-12T16:21:19Z

← Older revision		Revision as of 16:21, 12 September 2017
Line 35:		Line 35:

	==Clinical Freatures==		==Clinical Freatures==
			''Symptoms generally occur within 24-48 hours after taking drug''
	*[[Headache]]		*[[Headache]]
	*[[Fever]]		*[[Fever]]
Line 62:		Line 63:

	==Disposition==		==Disposition==

			==Outcome==
			*Generally good, usually with no long term sequelae

2017-09-12T16:09:33Z

← Older revision		Revision as of 16:09, 12 September 2017
Line 24:		Line 24:
	**OKT3 monoclonal antibodies		**OKT3 monoclonal antibodies
	*Misc		*Misc
	**[[Sulfasalazine]]		**Sulfasalazine
	**[[Carbamazepine]]		**[[Carbamazepine]]
	**[[Azathioprine]]		**[[Azathioprine]]
Line 31:		Line 31:
	**[[Ranitidine]]		**[[Ranitidine]]
	**[[Famotidine]]		**[[Famotidine]]
	**[[Methylprednisolone acetate]]		**Methylprednisolone acetate
	**[[Allopurinol]]		**[[Allopurinol]]

2017-09-12T16:08:52Z

2017-09-08T04:01:02Z

Differential Diagnosis

2017-09-08T04:00:04Z

2017-09-07T05:43:20Z

← Older revision		Revision as of 05:43, 7 September 2017
Line 6:		Line 6:
	*Higher predominance in SLE and female gender		*Higher predominance in SLE and female gender

	==Causes==		===Causes===
	*[[NSAIDs]]		*[[NSAIDs]]
	**Most common cause		**Most common cause
Line 34:		Line 34:
	**[[Allopurinol]]		**[[Allopurinol]]

	==Clinical ~~presentation~~==		==Clinical Freatures==
	*[[Headache]]		*[[Headache]]
	*[[Fever]]		*[[Fever]]
Line 43:		Line 43:
	*Less common symptoms include rash, arthralgia, myalgia, facial edema		*Less common symptoms include rash, arthralgia, myalgia, facial edema

	==Diagnosis==		==Differential Diagnosis==


			==Evaluation==
	*Drug history with focus on time of ingestion and symptom onset		*Drug history with focus on time of ingestion and symptom onset
	*CSF studies		*CSF studies
Line 55:		Line 58:
	**Due to associated risk, should only be done if suspected drug is irreplaceable		**Due to associated risk, should only be done if suspected drug is irreplaceable

	==~~Treatment~~==		==Management==
	*Discontinuation of offending agent		*Discontinuation of offending agent

			==Disposition==


			==See Also==


	==References==		==References==
	~~Moris, G, Garcia-Monco, JC. The Challenge of Drug-induced Aseptic Meningitis. Arch intern med. 1999 Jun 14; 159 (11): 1185-94~~		<references/>

	~~Nettis, E, Calogiuri, G, Colanardi, MC, Ferrannini, A, Tursi, A. Drug-induced Aseptic Meningitis. Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 2003, 3, pp. 143-149~~		[[Category:ID]]
			[[Category:Pharmacology]]

2017-09-01T19:41:02Z

References

← Older revision		Revision as of 19:41, 1 September 2017
Line 59:		Line 59:

	==References==		==References==
	Moris, G, Garcia-Monco, JC. The ~~challenge~~ of ~~drug~~-induced ~~aseptic meningitis~~. Arch intern med. 1999 Jun 14; 159 (11): 1185-94		Moris, G, Garcia-Monco, JC. The Challenge of Drug-induced Aseptic Meningitis. Arch intern med. 1999 Jun 14; 159 (11): 1185-94
	Nettis, E, Calogiuri, G, Colanardi, MC, Ferrannini, A, Tursi, A. Drug-induced ~~aseptic meningitis~~. Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 2003, 3, pp. 143-149
			Nettis, E, Calogiuri, G, Colanardi, MC, Ferrannini, A, Tursi, A. Drug-induced Aseptic Meningitis. Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 2003, 3, pp. 143-149

2017-09-01T19:39:50Z

← Older revision		Revision as of 19:39, 1 September 2017
Line 33:		Line 33:
	**[[Methylprednisolone acetate]]		**[[Methylprednisolone acetate]]
	**[[Allopurinol]]		**[[Allopurinol]]
	==Clinical presentation==
			==Clinical presentation==
	*[[Headache]]		*[[Headache]]
	*[[Fever]]		*[[Fever]]
Line 53:		Line 54:
	**Requires informed written consent		**Requires informed written consent
	**Due to associated risk, should only be done if suspected drug is irreplaceable		**Due to associated risk, should only be done if suspected drug is irreplaceable

			==Treatment==
			*Discontinuation of offending agent

			==References==
			Moris, G, Garcia-Monco, JC. The challenge of drug-induced aseptic meningitis. Arch intern med. 1999 Jun 14; 159 (11): 1185-94
			Nettis, E, Calogiuri, G, Colanardi, MC, Ferrannini, A, Tursi, A. Drug-induced aseptic meningitis. Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 2003, 3, pp. 143-149

2017-09-01T18:53:35Z

Background

← Older revision		Revision as of 18:53, 1 September 2017
Line 4:		Line 4:
	**Direct meningeal irritation by intrathecal drug		**Direct meningeal irritation by intrathecal drug
	**Hypersensitivity reaction to drug (type III and IV)		**Hypersensitivity reaction to drug (type III and IV)
			*Higher predominance in SLE and female gender

	==Causes==		==Causes==
	*[[NSAIDs]]		*[[NSAIDs]]

2017-09-01T18:39:40Z

Clinical presentation

← Older revision		Revision as of 18:39, 1 September 2017
Line 37:		Line 37:
	*[[Nausea/vomiting]]		*[[Nausea/vomiting]]
	*General malaise		*General malaise
			*[[Altered mental status]]
	*Less common symptoms include rash, arthralgia, myalgia, facial edema		*Less common symptoms include rash, arthralgia, myalgia, facial edema

	==Diagnosis==		==Diagnosis==
	*Drug history with focus on time of ingestion and symptom onset		*Drug history with focus on time of ingestion and symptom onset